Novo Nordisk launches a next generation of FlexPen®
- Details
- Category: Novo Nordisk
![Novo Nordisk Novo Nordisk](http://www.worldpharmanews.com/images/stories/logo/novonordisk_b.gif)
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon
- Details
- Category: Pfizer
![Pfizer Inc Pfizer Inc](http://www.worldpharmanews.com/images/stories/logo/pfizer_b.gif)
TRANSCEND® trial confirms long-term protective benefits and excellent tolerability profile
- Details
- Category: Boehringer Ingelheim
![Boehringer Ingelheim Boehringer Ingelheim](http://www.worldpharmanews.com/images/stories/logo/boehringeringelheim.gif)
Anavex completes successful preclinical studies on lead Alzheimer's drug candidate
- Details
- Category: Clinical Trials
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, today announced the successful completion of preclinical studies (in-vitro and in-vivo in mice) on ANAVEX 2-73, a novel sigma-1 receptor agonist for the treatment of Alzheimer's disease.
Novartis decides not to pursue further development of Aurograb(TM)
- Details
- Category: Novartis
![Novartis Novartis](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November
- Details
- Category: Bayer
![The Bayer Group The Bayer Group](http://www.worldpharmanews.com/images/stories/logo/bayer.gif)
Abbott Fund to Build First Pediatric HIV/AIDS Clinic in Tanzania
- Details
- Category: Abbott
![Abbott Abbott](http://www.worldpharmanews.com/images/stories/logo/abbott.gif)
More Pharma News ...
- GlaxoSmithKline and Valeant Pharmaceuticals announce worldwide collaboration agreement
- Bristol-Myers Squibb and Pfizer Provide Update on Apixaban Clinical Development Program
- ADAGIO trial results show Azilect® slows progression of Parkinson's disease
- Brings complementary capabilities in India to address patient populations most at risk
- Alpharma Responds To Unsolicited Proposal By King Pharmaceuticals, Inc.
- King Proposes Acquisition of Alpharma for $33 Per Share in Cash
- New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer